Advisor Group’s Lisata Therapeutics LSTA Stock Holding History

Advisor Group’s Portfolio LSTA Stock Details LSTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$0	Hold	1	–	–	﹤0.01%	5387
2019 Q3	$0	Hold	1	–	–	﹤0.01%	5354
2019 Q2	$0	Hold	1	–	–	﹤0.01%	5301
2019 Q1	$0	Hold	1	–	–	﹤0.01%	5272
2018 Q4	$0	Hold	1	–	–	﹤0.01%	5169
2018 Q3	$0	Hold	1	–	–	﹤0.01%	5164
2018 Q2	$0	Hold	1	–	–	﹤0.01%	4992
2018 Q1	$0	Hold	1	–	–	﹤0.01%	5016
2017 Q4	$0	Hold	1	–	–	﹤0.01%	5019
2017 Q3	$0	Sell	1 -53	-98%	-$3.22K	﹤0.01%	4906
2017 Q2	$4K	Buy	54 +53	+5,300%	+$3.74K	﹤0.01%	4328
2017 Q1	$0	Sell	1 -1	-50%	-$69	﹤0.01%	4748
2016 Q4	$0	Buy	2 +1	+100%	+$57	﹤0.01%	4569
2016 Q3	$0	Hold	1	–	–	﹤0.01%	4550
2016 Q2	$0	Buy	+1	New	+$92	﹤0.01%	4447

Other funds holding LSTA

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

WesBanco Bank Wheeling, West Virginia $3.61B AUM 24.09% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Advisor Group's LSTA Position: Q4 2019 in Review

Advisor Group held its Lisata Therapeutics (LSTA) position steady in Q4 2019 at 1 share worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5387.

Advisor Group first reported a position in LSTA in Q2 2016 and has held it in 15 quarters since. The position peaked at $4K in Q2 2017. 23 funds tracked by Wall St. Rank hold LSTA as of Q4 2019.

Advisor Group held 1 share of Lisata Therapeutics worth $0 as of Q4 2019.
Advisor Group left its Lisata Therapeutics share count unchanged in Q4 2019.
Lisata Therapeutics made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #5387 holding.
Advisor Group first reported a position in Lisata Therapeutics in Q2 2016 and has held it in 15 quarters since.
Advisor Group's Lisata Therapeutics position peaked at $4K in Q2 2017.
23 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.